Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine - AbbVie

Next Previous
X
Search
Drug Profile

Brimonidine - AbbVie

Alternative Names: AGN 190342; AGN 190342LF; Aiphagan Ophthalmic Solution 0.1%; Alphagan; Alphagan P; Alphagan Z; Brimonidine tartrate; DE 087; SNJ-2022; UK 1430 18; UK 14304

Latest Information Update: 21 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AbbVie; Allergan; Senju Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Bromobenzenes; Diamines; Eye disorder therapies; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic nerve disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • No development reported Dry age-related macular degeneration; Retinal detachment; Retinitis pigmentosa
  • Discontinued Neurological disorders

Most Recent Events

  • 08 Apr 2021 No development reported - Phase-II for Dry age-related macular degeneration in France, Portugal, Philippines, South Korea, Italy, Germany, Australia, USA (Intravitreous)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 30 Oct 2018 Efficacy data from the phase II BEACON trial in Dry age-related macular degeneration released by Allergan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top